BRAIN Biotech
Update in progressBNN.DE (XETRA)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorBasic Materials
- IndustrySpecialty Chemicals
BRAIN Biotech AG develops bio-based products in Germany, the US, France, the Netherlands and the United Kingdom. It operates in two segments: BRAINBiocatalysts, which develops, produces and markets enzymes, microorganisms and ingredients; and BRAINBioIncubator, a pipeline of R&D projects for the life sciences industry. Its offerings support foods, animal feed, cosmetics, medical products, and industrial applications. Founded 1993, headquartered in Zwingenberg, Germany; renamed in 2021.
Company score
- Sentiment
- 0.40
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.24
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.13
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketXETRA (GER)
- LocationGermany
- CEOMr. Adriaan Moelker
- Founded1993
- Employees280
- Websitewww.brain-biotech.com
Identifiers
- ISINDE0005203947